Rate of Polypharmacy and Its Determinants Among Older Adult Cardiovascular Patients at Hiwot Fana Comprehensive Specialized Hospital in Eastern Ethiopia

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2024-01-01 DOI:10.1016/j.curtheres.2024.100752

Shambel Nigussie MSc , Fekade Demeke Bayou MPH

{"title":"Rate of Polypharmacy and Its Determinants Among Older Adult Cardiovascular Patients at Hiwot Fana Comprehensive Specialized Hospital in Eastern Ethiopia","authors":"Shambel Nigussie MSc , Fekade Demeke Bayou MPH","doi":"10.1016/j.curtheres.2024.100752","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Understanding the rate of polypharmacy in cardiovascular patients is crucial because of its increasing occurrence and its association with potentially inappropriate prescribing practices and negative health outcomes, particularly among elderly individuals with cardiovascular conditions. According to the best of the literature search knowledge, the magnitude of polypharmacy and associated factors were not known among older cardiovascular patients in eastern Ethiopia.</p></div><div><h3>Objective</h3><p>The aim of this study was to assess the rate of polypharmacy and its determinants among older adult cardiovascular patients at Hiwot Fana Comprehensive Specialized Hospital in eastern Ethiopia.</p></div><div><h3>Methods</h3><p>A cross-sectional study design was undertaken, involving a cohort of 364 individuals aged 65 years and older who were receiving follow-up care for cardiovascular disease. A data abstraction sheet was used to gather the data. The convenience sampling technique was employed. To identify factors related to the rate of polypharmacy, multivariable logistic regression analysis was employed.</p></div><div><h3>Results</h3><p>The analysis included the medical records of 325 patients, revealing a polypharmacy prevalence rate of 20.7%. Individuals who were 77 years of age or older had a 1.12 times higher likelihood of having polypharmacy than individuals who were 65 to 70 years old. The presence of comorbidities along with cardiovascular diseases was a significant factor related to polypharmacy. Polypharmacy was prevalent among individuals with a larger number of comorbidities.</p></div><div><h3>Conclusions</h3><p>This study reported that 1 in 5 cardiovascular patients at a chronic care clinic experienced polypharmacy. Age (≥77 years), having comorbidities, number of comorbid diseases (≥3), duration of cardiovascular disease (≥5 years), and number of years taking cardiovascular drugs (≥5) were associated with higher odds of polypharmacy. Health care providers should be cautious about prescribing multiple medications to this population. Training in the prevention of inappropriate polypharmacy is crucial to reducing the trend of polypharmacy and its associated burden.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100752"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000225/pdfft?md5=a900521557a4a8a112f46fa9d00d35b4&pid=1-s2.0-S0011393X24000225-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X24000225","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Understanding the rate of polypharmacy in cardiovascular patients is crucial because of its increasing occurrence and its association with potentially inappropriate prescribing practices and negative health outcomes, particularly among elderly individuals with cardiovascular conditions. According to the best of the literature search knowledge, the magnitude of polypharmacy and associated factors were not known among older cardiovascular patients in eastern Ethiopia.

Objective

The aim of this study was to assess the rate of polypharmacy and its determinants among older adult cardiovascular patients at Hiwot Fana Comprehensive Specialized Hospital in eastern Ethiopia.

Methods

A cross-sectional study design was undertaken, involving a cohort of 364 individuals aged 65 years and older who were receiving follow-up care for cardiovascular disease. A data abstraction sheet was used to gather the data. The convenience sampling technique was employed. To identify factors related to the rate of polypharmacy, multivariable logistic regression analysis was employed.

Results

The analysis included the medical records of 325 patients, revealing a polypharmacy prevalence rate of 20.7%. Individuals who were 77 years of age or older had a 1.12 times higher likelihood of having polypharmacy than individuals who were 65 to 70 years old. The presence of comorbidities along with cardiovascular diseases was a significant factor related to polypharmacy. Polypharmacy was prevalent among individuals with a larger number of comorbidities.

Conclusions

This study reported that 1 in 5 cardiovascular patients at a chronic care clinic experienced polypharmacy. Age (≥77 years), having comorbidities, number of comorbid diseases (≥3), duration of cardiovascular disease (≥5 years), and number of years taking cardiovascular drugs (≥5) were associated with higher odds of polypharmacy. Health care providers should be cautious about prescribing multiple medications to this population. Training in the prevention of inappropriate polypharmacy is crucial to reducing the trend of polypharmacy and its associated burden.

查看原文本刊更多论文

埃塞俄比亚东部 Hiwot Fana 综合专科医院老年心血管病人的多重用药率及其决定因素

背景了解心血管病人的多重用药率至关重要，因为其发生率越来越高，而且与潜在的不当处方行为和不良健康后果有关，尤其是在患有心血管疾病的老年人中。本研究的目的是评估埃塞俄比亚东部 Hiwot Fana 综合专科医院老年心血管病患者的多重用药率及其决定因素。研究方法采用横断面研究设计，涉及接受心血管疾病后续治疗的 364 名 65 岁及以上的患者。研究采用数据摘要表收集数据。采用了方便抽样技术。结果分析包括 325 名患者的医疗记录，结果显示多种药物的使用率为 20.7%。77 岁或以上的患者使用多种药物的可能性是 65 至 70 岁患者的 1.12 倍。合并症和心血管疾病是导致多重用药的重要因素。结论这项研究表明，在慢性病诊所就诊的心血管病患者中，每5人中就有1人有多重用药的经历。年龄（≥77 岁）、合并症、合并症数量（≥3 种）、心血管疾病病程（≥5 年）和服用心血管药物的年数（≥5 年）与较高的多重用药几率相关。医疗服务提供者在为这类人群开具多种药物处方时应谨慎。预防不当多药治疗的培训对于减少多药治疗趋势及其相关负担至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.